Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Canopy Growth synthesizes cannabinoid CB1 and CB2 receptor ligands

Feb. 9, 2021

Onxeo partners with Institut Curie to study AsiDNA with radiotherapy in pediatric high-grade glioma

Feb. 9, 2021

Phase I trial of IDE-397 for solid tumors with MTAP deletion cleared to begin in U.S.

Feb. 8, 2021

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Feb. 8, 2021

Single-cell resolution reveals cell type, targets, for neuroblastoma

Feb. 8, 2021

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Feb. 8, 2021

Pfizer presents new TLR agonists

Feb. 8, 2021

Ono Pharmaceutical divulges KDM5A inhibitors

Feb. 8, 2021

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Feb. 5, 2021

CEACAM7 is a therapeutic target for CART therapy in PDAC

Feb. 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...